Company TrovaGene Inc Nasdaq
Equities
US8972383090
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Therapies for Cancers
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +26.42% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +26.42% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Mark Erlander
CEO | Chief Executive Officer | 64 | 04/13/04 |
James Levine
DFI | Director of Finance/CFO | 53 | 12/21/12 |
Tod Smeal
CTO | Chief Tech/Sci/R&D Officer | 59 | 11/22/11 |
Chief Tech/Sci/R&D Officer | - | 31/23/31 | |
Vicki Kelemen
COO | Chief Operating Officer | - | 01/15/01 |
Charles Monahan
LAW | General Counsel | - | 11/22/11 |
Brigitte Lindsay
PRN | Corporate Officer/Principal | - | 01/12/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
James Armitage
BRD | Director/Board Member | 77 | 22/20/22 |
Gary Pace
BRD | Director/Board Member | 76 | 22/20/22 |
Mark Erlander
CEO | Chief Executive Officer | 64 | 04/13/04 |
Lâle White
BRD | Director/Board Member | 68 | 22/20/22 |
Mani Mohindru
BRD | Director/Board Member | 52 | 10/21/10 |
Rodney Markin
CHM | Chairman | 67 | 19/14/19 |
Renee Tannenbaum
BRD | Director/Board Member | 72 | 10/21/10 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 44,724,591 | 41,348,436 ( 92.45 %) | 0 | 92.33 % |
Stock B | 0 | 60,600 | 0 | 0 |
Company contact information
Cardiff Oncology, Inc.
11055 Flintkote Avenue
92121, San Diego
+858 952 7570
http://www.cardiffoncology.comSector
1st Jan change | Capi. | |
---|---|---|
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |